Amneal Pharmaceuticals, Inc.
AMRX · XNASCIK 1723128fmd_10973ZSNMKMETA1EWC90F7NBMRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,018 | 1,034 | 1,663 | 1,626 | 1,993 | 2,094 | 2,212 | 2,394 | 2,794 | 3,019 |
| Cost of revenue | 421 | 507 | 939 | 1,147 | 1,330 | 1,325 | 1,428 | 1,573 | 1,774 | 1,905 |
| Gross profit | 597 | 526 | 716 | 353 | 628 | 769 | 785 | 821 | 1,020 | 1,113 |
| Research and development | 179 | 171 | 194 | 188 | 180 | 202 | 196 | 164 | 191 | 186 |
| Selling, general and administrative | 119 | 109 | 228 | 290 | 327 | 366 | 400 | 430 | 476 | 527 |
| Operating income | 285 | 245 | (20) | (249) | 91 | 153 | (95) | 204 | 249 | 394 |
| Other non-operating income (expense) | (70) | (74) | (183) | 28 | (127) | (121) | (153) | (245) | (304) | (255) |
| Income before taxes | 215 | 171 | (203) | (220) | (36) | 31 | (248) | (40) | (55) | 139 |
| Income tax expense | 5 | 2 | (1) | 383 | (104) | 11 | 7 | 8 | 19 | 11 |
| Net income from continuing operations | 209 | 169 | (201) | (604) | 69 | 20 | (255) | (49) | (74) | 128 |
| Net income | 0 | 0 | (20) | (604) | 68 | 13 | (271) | (84) | (117) | 72 |
| Net income to common shareholders | 0 | 0 | (21) | (362) | 91 | 11 | (130) | (84) | (117) | 72 |